Dicerna Pharmaceuticals, which is developing RNAi therapeutics for the treatment of rare liver disease and cancer, raised $90 million by offering 6.0 million shares at $15.00, above expectations. Dicerna Pharmaceuticals plans to list on the NASDAQ under the symbol DRNA. Dicerna Pharmaceuticals initially filed confidentially on 11/8/2013. Jefferies & Co., Leerink Partners and Stifel acted as joint bookrunners on the deal.
